{"created":"2023-07-25T10:25:22.309053+00:00","id":5664,"links":{},"metadata":{"_buckets":{"deposit":"4ceea91a-b8e5-4aec-9b23-9c854661b526"},"_deposit":{"created_by":3,"id":"5664","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"5664"},"status":"published"},"_oai":{"id":"oai:air.repo.nii.ac.jp:00005664","sets":["611:862:863:1482"]},"author_link":["15978","15977","15976","15981","15979","15980"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022-03-31","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3/4","bibliographicPageEnd":"98","bibliographicPageStart":"85","bibliographicVolumeNumber":"48","bibliographic_titles":[{"bibliographic_title":"秋田医学"}]}]},"item_10001_description_5":{"attribute_name":"内容記述（抄録）","attribute_value_mlt":[{"subitem_description":"Stereotactic body radiotherapy (SBRT) uses hypofractionated and more precise irradiation methods, and has the advantages of shorter duration, better outcomes, and fewer side effects than conventional radiotherapy. However, the optimal dosage remains unclear. The purpose of the study was to analyze our preliminary treatment results and safety. We retrospectively analyzed 32 patients (primary cancer, 22 ; metastatic cancer, 10) who underwent SBRT for pulmonary tumors at our hospital from April 2015 to June 2020. SBRT was performed with escalated dose prescriptions (up to 55Gy in 4 fractions/64Gy in 8 fractions for peripheral/central lesions, respectively). We evaluated the local control rate (LC rate), overall survival (OS), progression-free survival (PFS), disease-specific survival (DSS), and adverse events. The target lesions comprised 22 primary lung cancers and 13 metastatic lung cancers. The 2-year LC, OS, PFS, and DSS rates were 82.5%, 68.3%, 50.5%, and 88.0% for primary lung cancer patients and 83.1%, 29.9%, 23.1%, and 48.6% for metastatic lung cancer patients, respectively. Five cases of radiation pneumonitis of grade 2 or higher, one of grade 1 dermatitis and 1 of esophagitis were observed as adverse events. We showed that the treatment outcomes of SBRT for primary and metastatic lung cancers were mostly acceptable.","subitem_description_type":"Other"}]},"item_10001_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.20569/00005977","subitem_identifier_reg_type":"JaLC"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"秋田医学会"}]},"item_10001_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AN00009294","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0386-6106","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Satoshi, Kumagai"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yuki  Wada"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Akira Anbai"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Noriko Takagi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Eriko Okuyama"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Manabu Hashimoto"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-05-02"}],"displaytype":"detail","filename":"akitai48_3_4(85).pdf","filesize":[{"value":"741.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"akitai48_3_4(85).pdf","url":"https://air.repo.nii.ac.jp/record/5664/files/akitai48_3_4(85).pdf"},"version_id":"749d906c-2b16-4d3f-aaed-59e7c3d785af"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Stereotactic body radiotherapy","subitem_subject_scheme":"Other"},{"subitem_subject":" Stereotactic ablative radiotherapy","subitem_subject_scheme":"Other"},{"subitem_subject":" Lung cancer","subitem_subject_scheme":"Other"},{"subitem_subject":"Oligometastasis","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"SAFETY AND TREATMENT OUTCOMES OF STEREOTACTIC BODY RADIOTHERAPY FOR PULMONARY TUMORS : A RETROSPECTIVE SINGLE-CENTER STUDY","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"SAFETY AND TREATMENT OUTCOMES OF STEREOTACTIC BODY RADIOTHERAPY FOR PULMONARY TUMORS : A RETROSPECTIVE SINGLE-CENTER STUDY"}]},"item_type_id":"10001","owner":"3","path":["1482"],"pubdate":{"attribute_name":"公開日","attribute_value":"2022-05-02"},"publish_date":"2022-05-02","publish_status":"0","recid":"5664","relation_version_is_last":true,"title":["SAFETY AND TREATMENT OUTCOMES OF STEREOTACTIC BODY RADIOTHERAPY FOR PULMONARY TUMORS : A RETROSPECTIVE SINGLE-CENTER STUDY"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-07-25T10:44:02.786945+00:00"}